



October 17, 2025

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001
Scrip code: 532531

The National Stock Exchange of India Limited

Exchange Plaza, Bandra-Kurla Complex
Bandra (E) Mumbai - 400 051
Scrip code: STAR

Dear Madam/ Sir,

Sub: Press Release

Please find attached Press Release issued by the Company titled:

**“Strides and Incepta Partner to Expand Women’s Health Access with
WHO-Prequalified Contraceptive”**

Thanks & Regards,
For **Strides Pharma Science Limited**,

Manjula Ramamurthy
Company Secretary
ICSI Membership No. A30515

Encl. As above

Strides Pharma Science Limited

CIN: L24230MH1990PLC057062

Corp. Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru - 560 076, India

Tel: +91-80-6784 0000 **Fax:** +91 80 6784 0700

Regd Off: ‘Cyber One’, Unit No. 902, Plot No. 4 & 6, Sector 30A, Vashi, Navi Mumbai - 400 703, India

Tel: +91-22-2789 2924/ 3199

corpcomm@strides.com; www.strides.com

Strides and Incepta Partner to Expand Women's Health Access with WHO-Prequalified Contraceptive

Partnership to deliver affordable, high-quality contraceptive choice, empowering millions of women across the underserved regions

Key Highlights:

- WHO prequalification granted for the first generic version of subcutaneous depot medroxyprogesterone acetate (DMPA-SC).
- Strides to market the product Medogen SubQ in Africa as a brand, expanding access to safe and convenient contraceptive options.
- Reinforces Strides' commitment to women's health as a strategic priority and its focus on impactful global collaborations.

Bangalore, India, October 17, 2025 – Strides Pharma Science Limited today announced that one of its step-down wholly owned subsidiary will market the world's first **WHO-prequalified generic version of subcutaneous depot medroxyprogesterone acetate (DMPA-SC)** in Africa, strengthening women's access to affordable, quality reproductive health solutions.

Developed by **Incepta Pharmaceuticals** under the brand *Medogen SubQ*, and supported by the **Children's Investment Fund Foundation (CIFF)** and the **Gates Foundation**, the WHO prequalification marks a major breakthrough in reproductive health access. It diversifies supply of DMPA-SC, breaking the single-source bottleneck and helping health systems procure at more affordable prices.

DMPA-SC is a three-month contraceptive that can be administered by healthcare workers or self-injected after appropriate training. Its discretion, convenience, and empowerment potential make it a transformative choice for women, particularly in underserved low- and middle-income countries. With over **250 million women worldwide still lacking access to modern contraception**, the availability of a WHO-prequalified generic option represents a significant step toward meeting this unmet need.

Commenting on the milestone, Aditya Kumar, Executive Director, Business Development said:

"The collaboration with Incepta reflects our commitment to expanding access to safe, affordable and high-quality contraceptive medicines that help improve women's lives. By bringing the WHO-prequalified product to Africa, we aim to expand choice and access for women, enabling them to take greater control of their reproductive health. With this collaboration, Strides expands its Women's Health franchise in Africa, augmenting its existing portfolio of strong brands like Vitafer, L-Gest and many others. We are very excited to partner with Incepta to make available to a version of this easy-to-use, long -acting reversible contraceptive empowering women in the region to have greater control of their reproductive rights and choices.

"We are proud to have achieved WHO prequalification for our DMPA-SC product," said Abdul Muktadir, Chairman and Managing Director of Incepta Pharmaceuticals. "This accomplishment reflects our commitment to advancing public health and making essential medicines accessible to women across the world. We look forward to working with Strides to bring this product to market and improve reproductive health outcomes at scale."

This milestone reflects Strides' strategy of **leveraging global collaborations, regulatory excellence, and its strong Africa presence** to deliver impactful healthcare solutions. Women's health remains a cornerstone of Strides' branded generics portfolio, and the company continues to invest in partnerships that address pressing global health needs.

About Strides

Strides, a global pharmaceutical company headquartered in Bengaluru, India, is listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR). The Company mainly operates in the regulated markets and has an "in Africa for Africa" strategy and an institutional business to service donor-funded markets. The Company's global manufacturing sites are located in India (Chennai, Puducherry, and two locations in Bengaluru), Italy (Milan), Kenya (Nairobi), and the United States (New York). The Company focuses on "difficult to manufacture" products sold in over 100 countries. Additional information is available at the Company's website at www.strides.com.

About Incepta Pharmaceuticals

Incepta Pharmaceuticals Ltd. is a leading pharmaceutical company based in Bangladesh with a strong record of innovation, affordability, and public health commitment. Incepta produces a wide range of high-quality generic medicines and vaccines, and its growing portfolio of WHO-prequalified products including a DMPA-IM (intra-muscular) product that requires administration from a trained health provider, and supports health systems globally. More at: www.inceptapharma.com

For further information, please contact:

<u>Institutional Investors</u> Vikesh Kumar Group CFO & CIRO Email: investor-relations@strides.com Saurabh Ambaselkar Investor Relations - +91 99609 31220 Email: saurabh.ambaselkar@strides.com <u>Strides Pharma Science Limited</u> CIN: L24230MH1990PLC057062 Corp. Office: Strides House, Bannerghatta Road, Bengaluru – 560076	<u>Corporate Communication</u> Pallavi Panchmatia: +91 80 6784 0193 Email: pallavi.panchmatia@strides.com Abhilash Mukherjee: +91 80 6784 0193 Email: abhilash.mukherjee@strides.com Adrita Chatterjee: +91 92842 40813 adrita.chatterjee@adfactorspr.com
--	--